STOCK TITAN
  1. Home
  2. Sec-filings
  3. PROK
  4. [Form 4] PROKIDNEY CORP. Insider Trading Activity

ProKidney (PROK) director receives 135,000 stock options grant as compensation

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PROKIDNEY CORP. director Jennifer A. Fox received a grant of stock options as part of non-employee director compensation. She was awarded 135,000 director stock options, each allowing her to buy one share of Class A Common Stock at an exercise price of $1.81.

The options vest in full on the earlier of one year from the grant date or the company’s next annual general shareholder meeting and expire on May 28, 2036. After this grant, she holds 135,000 options directly, and this is a compensation award rather than an open-market share purchase.

Positive

  • None.

Negative

  • None.
Insider Fox Jennifer A.
Role null
Type Security Shares Price Value
Grant/Award Director stock option (right to buy) 135,000 $0.00 --
Holdings After Transaction: Director stock option (right to buy) — 135,000 shares (Direct, null)
Footnotes (1)
  1. These options were granted under the Issuer's non-employee director compensation policy. The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.
Options granted 135,000 options Director stock option grant on May 28, 2026
Exercise price $1.81 per share Director stock option grant
Expiration date May 28, 2036 Option term length
Underlying shares 135,000 shares Class A Common Stock underlying options
Post-transaction option holdings 135,000 options Total options held directly after grant
Director stock option financial
"Director stock option (right to buy)"
non-employee director compensation policy financial
"These options were granted under the Issuer's non-employee director compensation policy."
vest in full financial
"The options will vest in full on the sooner of the one-year anniversary"
Class A Common Stock financial
"underlying_security_title: Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Fox Jennifer A.
(Last)(First)(Middle)
C/O PROKIDNEY CORP
2000 FRONTIS PLAZA BLVD, SUITE 250
(Street)
WINSTON SALEM NORTH CAROLINA 27103
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
PROKIDNEY CORP. [ PROK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Director stock option (right to buy)$1.8105/28/2026A135,000(1) (2)05/28/2036Class A Common Stock135,000$0135,000D
Explanation of Responses:
1. These options were granted under the Issuer's non-employee director compensation policy.
2. The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.
/s/ Todd Girolamo, attorney in fact05/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did ProKidney (PROK) director Jennifer A. Fox report in this Form 4?

Jennifer A. Fox reported receiving a grant of 135,000 director stock options in ProKidney Corp. These options are part of the company’s non-employee director compensation policy and give her the right to buy Class A Common Stock at a fixed exercise price.

How many ProKidney (PROK) options did Jennifer A. Fox receive and at what exercise price?

She received 135,000 director stock options, each with an exercise price of $1.81 per share. These options relate to ProKidney’s Class A Common Stock and represent a compensation award rather than shares bought in the open market.

When do Jennifer A. Fox’s ProKidney (PROK) director stock options vest?

The options will vest in full on the earlier of one year from the grant date or the date of ProKidney’s next annual general shareholder meeting. This single-vesting schedule means all granted options become exercisable at that time, assuming continued service.

What is the expiration date of Jennifer A. Fox’s ProKidney (PROK) stock options?

The director stock options granted to Jennifer A. Fox expire on May 28, 2036. After that expiration date, any unexercised options will lapse and can no longer be used to purchase ProKidney Class A Common Stock at the $1.81 exercise price.

How many ProKidney (PROK) options does Jennifer A. Fox hold after this transaction?

Following this grant, Jennifer A. Fox holds 135,000 stock options directly. The Form 4 shows this total as her shares underlying options following the transaction, reflecting the new award and providing context for her derivative position in ProKidney.

Is Jennifer A. Fox’s ProKidney (PROK) Form 4 transaction an open-market stock purchase?

No, the filing shows a grant of director stock options, not an open-market share purchase. The options were awarded under ProKidney’s non-employee director compensation policy with a $1.81 exercise price and future vesting, rather than bought for cash in the market.